The AiAIT task force aims to critically discuss the role of adjuvants and carriers in allergen immunotherapy, both in the context of tolerance induction or novel vaccination concepts. The Task force Adjuvants in Allergy was approved in November 2016.
· To evaluate the state of the art in established adjuvants
· To determine the immune effects associated with adjuvants
· To evaluate their risks and outweigh with the benefits
· To critically assess novel adjuvants and formulations potentially suitable in AIT
Picture: TF secretary Erika Jensen-Jarolim with TF chair Thomas Kündig